Digestive system neuroendocrine tumor, grade 1/2

This early-phase trial tests whether adding triapine to standard radioactive therapy (lutetium Lu 177 dotatate) is safe and effective for people with advanced neuroendocrine tumors of the digestive system. About 31 participants whose tumors have worsened after prior treatment wil…

This study tested a drug called pazopanib in 171 people with carcinoid tumors that were growing or spreading. The goal was to see if pazopanib could slow tumor growth better than a placebo. Participants were randomly assigned to receive either pazopanib or a placebo, and research…

This early-phase study is testing whether giving a radioactive drug called Lutathera both before and after surgery is safe for people with advanced neuroendocrine tumors that have spread to the liver or lymph nodes. The trial will enroll 10 adults whose tumors are considered remo…

This phase 3 trial tests whether a radioactive drug called 177Lu-Edotreotide (PRRT) works better than the daily pill everolimus for people with advanced neuroendocrine tumors of the gut or pancreas that can't be removed by surgery. About 324 participants are randomly assigned to …

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …

This phase 3 trial compares a new form of octreotide (CAM2029) given as a shot every 2 weeks to standard monthly injections in 332 people with advanced neuroendocrine tumors of the gut or pancreas. The main goal is to see if the new drug delays tumor growth better than current tr…

This phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…

This early-phase trial tests a new drug (peposertib) combined with a radioactive therapy (lutetium 177 dotatate) for people with a type of slow-growing gut and pancreas cancer called neuroendocrine tumors. The goal is to find the safest dose and see if the combination shrinks tum…

This Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…

This early study tests whether giving the drug Lutathera directly into the liver artery is safe and practical for people with neuroendocrine tumors that have spread mainly to the liver. Ten participants will receive two doses into the liver artery followed by two standard IV dose…

This early-phase study tests a radioactive drug (177Lu-PP-F11N) that seeks out and attaches to cancer cells in people with advanced medullary thyroid cancer and certain other neuroendocrine tumors. The goal is to see if the drug can help image tumors and deliver targeted radiatio…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This study is testing a radioactive drug called Lutathera in teenagers aged 12 to 17 who have rare tumors of the digestive system or adrenal glands. The goal is to see if the drug is safe and how much radiation reaches organs. Eleven teens are taking part, and researchers are wat…

This study tested whether adding Lutathera to standard octreotide treatment can delay tumor growth in people with advanced neuroendocrine tumors of the stomach, intestines, or pancreas. The trial involved 226 patients with fast-growing tumors (grades 2 and 3) who had not received…

This phase 2 trial tests the drug abemaciclib (Verzenio) in 20 patients with advanced gastroenteropancreatic neuroendocrine tumors that have spread, are not responding to treatment, and cannot be surgically removed. The drug works by blocking enzymes that help cancer cells grow. …

This Phase 3 trial tests a radioactive drug called 177Lu-Edotreotide against standard chemotherapy for people with aggressive neuroendocrine tumors of the gut or pancreas. The drug targets tumor cells and delivers radiation directly. About 259 participants will be followed to see…

This Phase 3 study tested a radioactive drug called Lutetium-177 oxodotreotide against a high dose of the standard drug octreotide in 196 people with advanced neuroendocrine tumors that had stopped responding to treatment. The main goal was to see if the radioactive drug could de…

This study looks at whether a special type of CT scan, called dual energy CT, can better detect carcinoid tumors in the digestive system. About 71 people with signs or confirmed carcinoid tumors will get this scan during a routine check-up. The goal is to see if this imaging meth…

This study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 people with metastatic neuroendocrine tumors. The goal is to see if all tumors show up on the standard scan or if some are missed, which could change treatment. Participants will get …

This study follows over 2,500 people with neuroendocrine tumors (NETs) to understand their symptoms and how treatments are chosen. Participants fill out surveys about quality of life and care experiences over 18 months. Researchers will link this to medical records to find which …

This pilot study is testing whether combining two different PET scans can give doctors a clearer picture of neuroendocrine tumors (NETs) in the gut. The scans measure how tumors take up different tracers, which may reveal whether a tumor is slow-growing or aggressive. The goal is…

This study follows over 1,000 adults with advanced neuroendocrine tumors who have already been treated with Lutathera. Researchers are tracking long-term side effects, including the risk of new cancers, and overall survival. The goal is to better understand the drug's safety over…

This registry is collecting blood samples and health data from 400 people with neuroendocrine tumors. The goal is to see if a new blood test called NETest can help detect tumor activity and predict disease progression. Participants include patients before and after surgery, those…